Ibrutinib

ORLANDO — A chemoimmunotherapy regimen containing ibrutinib, fludarabine, cyclophosphamide and obinutuzumab resulted in high rates of clinical remission and undetectable minimal residual disease in previously untreated patients with chronic lymphocytic leukemia who harbor IGHV mutations but lack 17p deletions and TP53 mutations, according to data presented at the ASH Annual Meeting and Exposition.

ORLANDO — Adverse events from treatment for chronic lymphocytic leukemia appeared common among Medicare patients treated in a real-world setting, which contributed to a substantial economic burden for these patients, according to results of a population-based retrospective cohort study presented at ASH Annual Meeting and Exposition.

Ibrutinib, a paradigm-changing drug for the treatment of various blood cancers, appeared to be more closely associated with new or worsened hypertension than previously thought, according to results of a study published in Blood.

In this video, Pooja Khandelwal, MD, an associate professor at the University of Cincinnati's Department of Pediatrics, discusses the latest in the treatment and study of graft-versus-host disease, including new innovations for the treatment of chronic cases.

Healio spoke with Shazia K. Nakhoda, MD, about CLL highlights from recent conferences.

Healio spoke with Shazia K. Nakhoda, MD, about incorporating new therapies into practice.

Healio spoke with Shazia K. Nakhoda, MD, about recent approvals and advancements in the management of CLL.

Healio spoke with Ryan. W. Jacobs, MD, about complications that can arise in patients with CLL.

Healio spoke with Ryan. W. Jacobs, MD, about research needs in CLL.

Healio spoke with Ryan. W. Jacobs, MD, about new treatments in the pipeline for CLL.